A Phase I Single Center Study Evaluating 68GA-FAPI-46 PET/CT in Patients With Interstitial Lung Disease

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT07817563
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Interstitial Lung Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ⁶⁸Ga-FAPI-46 — DRUG
    Subjects will have 68Ga-FAPI-46 intravenously administered
  • PET/CT — DIAGNOSTIC_TEST
    Subjects will complete a PET/CT approximately 60-70 minutes after being given ⁶⁸Ga-FAPI-46

Study Details

The purpose of this research is to better understand the distribution of an investigational radioactive imaging agent called 68Ga-FAPI-46 in the lungs of people with interstitial lung disease (ILD) during a Positron Emission Tomography/Computed Tomography (PET/CT) scan.

Key Dates

First listed
Sep 14, 2026
Start date
Oct 16, 2026
Status verified
Sep 2026
Primary completion
May 31, 2030
Completion
May 31, 2031

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: ⁶⁸Ga-FAPI-46 PET/CT
    Subjects with interstitial lung disease will have a dose of 3 - 7 mCi (111 - 185MBq) of ⁶⁸Ga-FAPI-46 administered intravenously

Primary Outcome Measure

Maximum Standardized Uptake Value in Abnormal Lung Parenchyma [ Time Frame: Approximately 1 hour post injection ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905-

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MN

Related Studies